Eli Lilly and Company (NYSE:LLY) Shares Acquired by Pure Financial Advisors LLC

Pure Financial Advisors LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 13.7% during the first quarter, HoldingsChannel.com reports. The firm owned 3,873 shares of the company’s stock after acquiring an additional 466 shares during the period. Pure Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $3,199,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Security National Bank lifted its stake in shares of Eli Lilly and Company by 643.6% in the 1st quarter. Security National Bank now owns 1,502 shares of the company’s stock valued at $1,241,000 after purchasing an additional 1,300 shares in the last quarter. Omnia Family Wealth LLC lifted its holdings in shares of Eli Lilly and Company by 10.5% during the 1st quarter. Omnia Family Wealth LLC now owns 2,261 shares of the company’s stock valued at $1,868,000 after acquiring an additional 214 shares in the last quarter. New World Advisors LLC boosted its position in Eli Lilly and Company by 47.9% during the 1st quarter. New World Advisors LLC now owns 1,078 shares of the company’s stock worth $890,000 after purchasing an additional 349 shares during the period. Alpine Bank Wealth Management acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $903,000. Finally, FFG Partners LLC increased its holdings in Eli Lilly and Company by 3.9% in the 1st quarter. FFG Partners LLC now owns 20,856 shares of the company’s stock valued at $17,226,000 after purchasing an additional 783 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on LLY. Hsbc Global Res downgraded Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. UBS Group reduced their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. HSBC lowered shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and dropped their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Finally, Erste Group Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,011.61.

Eli Lilly and Company Price Performance

LLY opened at $795.97 on Friday. The company has a market capitalization of $754.37 billion, a P/E ratio of 64.77, a PEG ratio of 1.16 and a beta of 0.40. The company has a 50-day moving average of $781.50 and a 200-day moving average of $800.11. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the prior year, the firm earned $2.58 earnings per share. The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. Equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.75%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.